Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + oral cyclophosphamide + dexamethasone in relapsed/refractory multiple myeloma (Phase II)
KCT0008537Phase 2Not yet recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Dec 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by JW Pharmaceutical Corporation. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0008537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008537.